In accordance with the guidelines for bioequivalence testing,

bioequivalence was assumed when the ratio test/reference fell within the 90 % CI 80–125 reference range. The alpha error was set at 0.05 to define statistical significance. The pharmacokinetic parameters and analyses were calculated using WinNonlin Version 5.2 (Pharsight Corporation, Mountain View, CA, USA). The statistical package SAS version 9.2 (SAS Institute Inc, Cary, NC, USA) was used Anlotinib clinical trial in some computations. 2.5 Safety Assessments Safety and tolerability assessments included routine laboratory tests (blood chemistries, hematological profile, coagulation and urinalysis), physical examination, ECG and vital signs. Any undesirable sign, symptom or medical condition occurring after starting this website the study, whether reported spontaneously or when prompted, was recorded regardless of suspected relation to the study medications. 3 Results 3.1 Population A total of 40 healthy subjects were randomized to the study, 20 (20) in each dosage strength (400 and 800 mg

ESL). The overall mean ± SD (range) demographic data were as follows: age = 35.7 ± 10.6 (range 20–54) years; height = 171 ± 9 (156–191) cm; BMI = 22.1 ± 1.9 (18.1–24.7) kg/m2. All subjects were exposed to ESL. Twenty (20) subjects (11 males and 9 females) received a single oral tablet of 400 mg ESL from both MF and TBM formulations. Thus, all subjects completed both periods of the 400 mg dosage strength and were selleck kinase inhibitor available for PK analysis. Twenty (20) subjects (10 males and 10 females) received a single oral tablet of 800 mg ESL of the MF formulation but only 18 subjects received a single oral tablet of 800 mg ESL of

the TBM formulation. Exoribonuclease Two (2) subjects discontinued the study before dosing on their second treatment period (ESL 800 mg TBM): one subject presented a positive result for opiates due to the intake of antitussive syrup, and the other withdrew the informed consent for personal reasons. Thus, 18 (18) subjects (10 males and 8 females) completed both periods of the 800-mg dosage strength and were available for PK analysis. 3.2 Pharmacokinetics 3.2.1 ESL ESL (parent) plasma concentrations were systematically found to be below the limit of quantification; therefore, the concentration-time profiles of ESL could not be displayed nor the PK parameters calculated. Thus, PK analysis was done exclusively for the main metabolite (BIA 2-005). 3.2.2 BIA 2-005 Mean plasma concentrations over time of BIA 2-005 following a single oral dose of ESL 400 mg MF and TBM formulations and ESL 800 mg MF and TBM formulations are presented in Fig. 1. Plasma drug concentration-time curves show that the mean concentrations of BIA 2-005 were similar for the two formulations (MF and TBM) over the entire sampling period and for both 400 and 800 mg dose strengths (Fig. 1). Fig.